Capital Markets: Equity (International Firms) - China
What the team is known for
With noted specialist strengths advising clients in thehealthcare, life sciences, technology and biotechnology sectors, O'Melveny & Myers regularly handles Hong Kong IPOs, advising both issuers and sponsors. The team is also equipped to handle H-share listings and listing transfers. Its key clients include RemeGen, Cryofocus Medtech and OrbusNeich.
Strengths
"They have consistently been number one for Hong Kong and US issuer counsel in the healthcare sector in the past few years. They have not only the legal capabilities but also the understanding of science to do this successfully; industry knowledge is critical in the healthcare sector."
"Nobody is more commercial and practical than them in the market. That’s one of the reasons why we like them."
Work highlights
O'Melveny & Myers represented Beauty Farm Medical and Health Industry in its approximately USD100 million IPO and listing of H-shares on the Main Board of the SEHK.
Notable practitioners
Geng Ke is head of O'Melveny & Myers' China capital markets team and managing partner of the firm's Beijing office. He regularly leads a range of listings across the biopharmaceutical, healthcare and life sciences sectors. "He is the industry expert in the healthcare sector; not only does he have a law degree but also a PhD in biochemistry." "Geng Ke is familiar with both US and Hong Kong IPOs. I'm impressed by his ability."
Zhu Ke is dual-qualified in New York and Hong Kong and is consistently called on to handle a range of healthcare, technology and life sciences equity capital markets transactions. "Zhu Ke is very knowledgeable on Hong Kong listing rules and very dependable." "Zhe Ke has an outstanding ability to solve complex problems."
